PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsCRISPR genome editing corrects a Duchenne muscular dystrophy deletion mutation in mice

BioNews

CRISPR genome editing corrects a Duchenne muscular dystrophy deletion mutation in mice

Published 30 April 2021 posted in News and appears in BioNews 1093

Author

Christina Burke

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Two genome editing approaches can correct a variety of mutations associated with Duchenne muscular dystrophy, researchers have shown...

Two genome editing approaches can correct a variety of mutations associated with Duchenne muscular dystrophy (DMD), researchers have shown.

DMD is a genetic disorder caused by mutations in the dystrophin gene, leading to a fatal decline in muscle integrity. For the first time, researchers have used two CRISPR-based genome editing techniques to correct multiple dystrophin mutations in mice. It is hoped this could pave the way for new genome editing therapies for DMD.

'Every cell in the human body has three billion letters of DNA sequence in its genome, and this method makes it possible to correct large deletions in the DMD gene by specifically swapping one of these letters,' said Professor Eric Olson, of the University of Texas Southwestern Medical Centre in Dallas, and senior author of the study. 'That level of specificity and efficiency is remarkable,' he added.

The study, published in Science Advances, investigated two methods of genome editing termed 'prime editing' and 'base editing'. The techniques are similar to the CRISPR/Cas9 approach, where specialised proteins are introduced into cells to make edits to genomic DNA, but they enable more precise changes to single DNA 'letters', called bases.

In a significant proportion of DMD patients, dystrophin mutations produce an errant 'stop' signal that halts production of functional protein. By changing single DNA bases, the researchers were able to bypass these mutations and restore 97 percent of functional dystrophin production in human heart muscle cells in vitro. When applied to a mouse model of DMD, functional dystrophin returned to over half of leg muscle fibres within three weeks.

'A lot more work needs to be done to develop the technology before it can be applied to patients – but this paper does represent a very promising step' said Professor Robin Lovell-Badge, from the Francis Crick Institute, London, not involved in the research. 'This study is therefore a pointer of which way to proceed in other situations where genome editing is being used to correct a defective gene.'

The findings have been hailed as an important proof-of-concept for base editing and prime editing, although the authors stressed that there is still a long way to go before these techniques can be translated to the clinic. For instance, in order to deliver the cargo of genome-editing proteins into cells, the team used a very high number of viral particles as vehicles – too high to safely trial in bigger animal models and humans.

Nevertheless, the research team are hopeful this method could one day be broadly applied to the treatment of DMD.

Professor Olson explained: 'The power of our method is that you don't need a new gene editing strategy for every patient with a new mutation; you can correct multiple different mutations with a consolidated approach.'

Sources and References

  • 30/04/2021
    Science Advances
    Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing
  • 30/04/2021
    University of Texas Southwestern
    New genome editing strategies developed for Duchenne muscular dystrophy

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 January 2022 • 2 minutes read

Gene therapy developed to treat limb-girdle muscular dystrophy

by Dr Holly Barker

A new gene therapy approach has shown promise in a preclinical mouse model for treating limb-girdle muscular dystrophy 2B, a rare genetic disorder which causes severe muscle weakness...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 July 2021 • 2 minutes read

CRISPR genome editing treatment shows promise for genetic disorder

by Dr Laura Riggall

In-body CRISPR-Cas9 genome editing could offer an effective treatment for a rare, life-threatening genetic condition...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
23 April 2021 • 2 minutes read

New CRISPR-based gene therapy for single-gene conditions

by Tsvetana Stoilova

A new genome editing approach that replaces a mutated gene with a functional gene copy has the potential to treat monogenic diseases...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 April 2021 • 2 minutes read

CRISPR gene therapy for sickle cell disease approved by the FDA

by Dr Molly Godfrey

A clinical trial for a new gene therapy approach to treat sickle cell disease has been approved to proceed by the US Food and Drug Administration...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
12 March 2021 • 4 minutes read

Event Review: Curing the Incurable — The promises of genome editing

by Dr Yvonne Collins

Scientific American in partnership with Cellectis, hosted a virtual event to explore genome editing and its use in the clinic. Three pioneers of the field were invited to discuss the early days of genome editing, new technologies and future challenges...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 August 2018 • 2 minutes read

Genome editing relieves muscular dystrophy in dogs

by Dr Charlott Repschläger

Dogs with Duchenne muscular dystrophy (DMD) have been treated using genome editing, a study in Science reports...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
23 October 2017 • 3 minutes read

'CRISPR-Gold' repairs muscular dystrophy gene in mouse model

by Emma Laycock

Scientists have repaired the faulty gene in a mouse model of muscular dystrophy by using gold nanoparticles to deliver the genome editing tool CRISPR-Cas9...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« New sequencing method for studying genetic changes in any human tissue

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856